On the other hand, whether the Asian populations in the J-ALEX and ALESIA trials demonstrated better ORR, PFS, OS, and CNS response under ALKI is an interesting issue, and further investigations are warranted to investigate the background immune status, tumor microenvironment, and variation of ALK gene rearrangements between Asian and Western populations. The gene discussed is ALK; the disease is neoplasm.